-

10:25:16 PM

FSTX Stock News

FSTX - F-star Therapeutics Inc

06/23/22 7:30 AM

Nasdaq : FSTX

acquisition

invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs

Proposed ~US$161 million all-cash acquisition to accelerate invoX’s strategy to build Sino Biopharm’s International Biopharmaceutical R&D Platform outside of China, transforming the lives of patients worldwide The transaction demonstrates the strength of F-star’s differentiated bispecific antibody

RHEA-AI

positive

05/10/22 8:00 AM

Nasdaq : FSTX

earnings

F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Four Clinical Readouts Anticipated Throughout 2022 Mechanistic Data on FS118 Demonstrating Shedding Mechanism and LAG-3 Reduction Presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting Company To Host Conference Call Today at 9:00 a.m. EDT CAMBRIDGE, United Kingdom and

RHEA-AI

neutral

05/02/22 9:00 AM

Nasdaq : FSTX

F-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that the

RHEA-AI

neutral

04/08/22 8:00 AM

Nasdaq : FSTX

F-star Therapeutics Presents a Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next

RHEA-AI

neutral

03/14/22 8:00 AM

Nasdaq : FSTX

earnings

F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update

Multiple Clinical Program Updates Expected in 2022 Continued Expansion of Leading Bispecific Antibody IP Estate Two New Significant Partnerships with Janssen and AstraZeneca Company to Host Conference Call Today at 9 a.m. EDT CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 14, 2022 (GLOBE

RHEA-AI

very positive

03/10/22 8:00 AM

Nasdaq : FSTX

conferences

F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that

RHEA-AI

neutral

03/02/22 8:00 AM

Nasdaq : FSTX

conferencesearnings

F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that the

RHEA-AI

neutral

03/01/22 8:00 AM

Nasdaq : FSTX

management

F-star Therapeutics Appoints James Sandy as Chief Development Officer

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that

RHEA-AI

very positive

01/20/22 8:00 AM

Nasdaq : FSTX

F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3

F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage

RHEA-AI

very positive

01/07/22 8:00 AM

Nasdaq : FSTX

conferences

F-star Therapeutics to Participate in Upcoming Investor Conferences

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next-generation bispecific immunotherapies to transform the lives of patients with cancer, today announced

RHEA-AI

neutral

FSTX Data

IndustryPharmaceutical Preparation Manufacturing
Websitef-star.com
Security nameF-star Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees77
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address35 Parkwood Dr Ste 210
StateMassachusetts
CityHopkinton
Zip01748-1699
CountryUS
Phone15084735993

About F-star Therapeutics Inc

F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company's goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star's mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.